A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 10, 2006, Pages 2632-2636

  Janser, Philipp ^a   Neumann, Ulf ^a   Miltz, Wolfgang ^a   Feifel, Roland ^a   Buhl, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Absorption; Bioavailability; Cassette dosing; Claisen Ireland rearrangement; Clearance; Dual; Inhibitor; Metalloproteinase; MMP; Oral; Pharmacokinetics; Rheumatoid arthritis; TACE; TNF ; TNF484; Trocade

Indexed keywords

CIPEMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; TNF 484; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; IN VIVO STUDY; NONHUMAN; RAT;

ADAM PROTEINS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; RATS;

ANIMALIA;

EID: 33645892563     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.02.042     Document Type: Article

References (17)

1. Risto A., and Veli-Matti K. Biochimie 87 (2005) 273
2. Handsley M.M., and Edwards D.R. Int. J. Cancer 115 (2005) 849
3. Tayebjee M.H., Lip G.Y.H., and MacFadyen R. J. Curr. Med. Chem. 12 (2005) 917
4. Kottirsch G., Koch G., Feifel R., and Neumann U. J. Med. Chem. 45 (2002) 2289
5. Trifilieff A., Walker C., Keller T., Kottirsch G., and Neumann U. Br. J. Pharmacol. 135 (2002) 1655
6. Meli D.N., Loeffler J.M., Baumann P., Neumann U., Buhl T., Leppert D., and Leib S.L. J. Neuroimmunol. 151 (2004) 6
7. Hemmings F.J., Farhan M., Rowland J., Banken L., and Jain R. Rheumatology 40 (2001) 537
8. Millar A.W., Brown P.D., Moore J., Galloway W.A., Cornish A.G., Lenehan T.J., and Lynch K.P. Br. J. Clin. Pharmacol. 45 (1998) 21
9. Lewis E.J., Bishop J., Bottomley K.M.K., Bradshaw D., Brewster M., Broadhurst M.J., Brown P.A., Budd J.M., Elliott L., Greenham A.K., Johnson W.H., Nixon J.S., Rose F., Sutton B., and Wilson K. Br. J. Pharmacol. 121 (1997) 540
10. Broadhurst M.J., Brown P.A., Lawton G., Ballantyne N., Borkakoti N., Bottomley K.M.K., Cooper M.I., Eatherton A.J., Kilford I.R., Malsher P.J., Nixon J.S., Lewis E.J., Sutton B.M., and Johnson W.H. Bioorg. Med. Chem. Lett. 7 (1997) 2299
11. Koch G., Kottirsch G., Wietfeld B., and Küster E. Org. Process Res. Dev. 6 (2002) 652
12. Koch G., Janser P., Kottirsch G., and Romero-Giron E. Tetrahedron Lett. 43 (2002) 4837
13. Roberts S.A. Xenobiotica 31 (2001) 557
14. Manitpisitkul P., and White R.E. Drug Discovery Today 9 (2004) 652
15. PK cassette-dosing in rats. The experiment was performed in conscious, fed, permanently cannulated rats kept under standard conditions. For oral administration by gavage, a mixture of ethanol (3%) and cornoil was used as a vehicle (5 mL/kg), whereas for the intravenous route compounds were administered into the femoral vein as a solution in N-methyl-2-pyrrolidone (30%) in polyethylene glycol 200 (0.5 mL/kg). Plasma samples of approximately 70 μL were collected from the femoral artery for 24 h after iv administration and for 7 h after oral dosing. iv and po administration was in the same animals with a 48 h washout period between administrations. After acetonitrile precipitation of plasma samples (25 μL), parent drug concentrations in extracts were measured using a specific HPLC/MS method. Complete details of the procedure are given as supporting information.
16. Neumann U., Kubota H., Frei K., Ganu V., and Leppert D. Anal. Biochem. 328 (2004) 66
17. 50 was determined.